Protocol Reference — MOTS-c

Protocol Type

Subcutaneous injection

Only validated route

Beginner Cycle

5 mg every 5 days × 4 injections (20 days)

Safe-default starting protocol

Advanced Cycle

5–15 mg per week for 4–8 weeks

Performance/recovery protocol followed by equivalent rest

Clinical Reference

25 mg daily for 4 weeks (CB4211 analog)

Phase 1b trial dose — NOT native MOTS-c

Rest Period

4 months minimum after beginner cycle

Precautionary — prevents signaling exhaustion

Cycle Rationale

Avoid receptor desensitisation and feedback loop disruption

No data confirms optimal rest period